Summary

This BMJ investigation asks whether the US claim of medical agreement on treating gender distress in young people is backed by evidence. Block looks at the three most-quoted US guidance documents (from WPATH, the American Academy of Pediatrics and the Endocrine Society) and interviews experts on how they were made. Research reviews behind these guidelines rated the evidence for teenagers as low or very low quality, yet strong recommendations were made, and the pediatrics statement was not based on a formal review of the research. Meanwhile Sweden, Finland and NHS England were restricting medical treatment. It documents real weaknesses in the US guidelines and showed a major journal took the debate seriously. But it is journalism: the reporter chose the sources and examples, some figures (such as 20–30% stopping hormones) come from limited studies, and some readers called it biased.

Key findings

• US medical groups (WPATH, the American Academy of Pediatrics and the Endocrine Society) support puberty blockers, cross-sex hormones and, in some cases, surgery for minors, while Sweden and Finland moved to put psychological care first and limit surgery to adults.
• The Endocrine Society used a formal system for rating evidence and rated the evidence for all its teen recommendations as 'low' or 'very low', yet sometimes made strong recommendations. Gordon Guyatt, a co-founder of that rating system, said this should be rare and clearly explained.
• WPATH's 2022 guidelines have no system for rating evidence. Guideline expert Mark Helfand found statements 'at odds with' the guideline's own research reviewers, who rated evidence on hormones' effects on quality of life, depression and anxiety as low quality.
• The lead author of the American Academy of Pediatrics' 2018 policy statement said its process did not quite count as a formal review of the research. Cochrane, a leading evidence review group, declined to publish a proposed puberty blocker review after expert checking.
• A McMaster University summary of 61 research reviews, paid for by Florida's Medicaid (public health insurance) agency, found 'great uncertainty' about blockers, hormones and surgery in young people.
• Two recent studies (a UK family doctor practice audit and US military pharmacy records) suggested 20–30% of patients may stop hormones within a few years, but these measured stopping, not regret or detransition.
• Clinicians described faster medical treatment and less mental health assessment. In a study at Seattle Children's clinic, two thirds of teens were on hormones within 12 months of their first visit.

Conclusion

This investigative report from The BMJ concludes that despite claims of consensus, gender-affirming medical treatments for minors with gender dysphoria lack strong evidence-based support. Key findings include: (1) US medical organizations (WPATH, AAP, Endocrine Society) endorse gender-affirming care including puberty blockers, hormones, and surgeries, while several European countries (Sweden, Finland, France, UK) have moved to restrict medical interventions for minors, prioritizing psychological care; (2) systematic reviews commissioned by guideline bodies found evidence quality to be "low" or "very low," with experts criticizing the misapplication of "evidence-based" labeling to recommendations not meeting rigorous standards; (3) the surge in treatment of minors—particularly birth-registered females with no prior history of gender dysphoria—has outpaced research, with long-term outcomes unknown and detransition rates potentially as high as 20-30%; (4) clinical practice has shifted toward rapid medicalization, with concerns about inadequate assessment and perfunctory informed consent processes; and (5) prominent evidence-based medicine experts conclude that when rigorous systematic reviews find "we don't know," claims of certainty are not evidence-based, and consensus-based guidelines should not be called evidence-based.